SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03647592

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.

NCT03647592 Non Small Cell Lung Cancer
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Erlotinib/Gefitinib combined with Bevacizumab

Description: Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
Type: Drug
Group Labels: 1

Cohorts 1


Primary Outcomes

Description: Progression free survival

Measure: PFS

Time: Approximately 1 years

Secondary Outcomes

Description: Overall survival

Measure: OS

Time: Approximately 1 years

Description: Disease control rate

Measure: DCR

Time: Approximately 1 years

Time Perspective: Retrospective

Cohort


There is one SNP

SNPs


1 L858R

Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Non Small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. --- L858R ---

Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Non Small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. --- L858R --- --- L858R ---



HPO Nodes


HPO: